|
Volumn 338, Issue 6112, 2012, Pages 1296-1297
|
U.S. regulation of stem cells as medical products
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CELL ORGANELLE;
DEVELOPMENTAL BIOLOGY;
GENE EXPRESSION;
GENETIC ANALYSIS;
NUMERICAL MODEL;
SAFETY;
STATE ROLE;
STEM;
EMBRYONIC STEM CELL;
GOVERNMENT;
HUMAN;
LAW;
MEDICAL ETHICS;
PATIENT SAFETY;
PLURIPOTENT STEM CELL;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
SHORT SURVEY;
STEM CELL;
UNITED STATES;
ARTICLE;
COMMERCIAL PHENOMENA;
FOOD AND DRUG ADMINISTRATION;
LEGAL ASPECT;
MESENCHYMAL STROMA CELL;
PRACTICE GUIDELINE;
PRODUCT SAFETY;
SAFETY;
STEM CELL TRANSPLANTATION;
UNITED STATES;
BIOLOGICAL PRODUCT;
BIOLOGICAL AGENTS;
COMMERCE;
CONSUMER PRODUCT SAFETY;
FEDERAL GOVERNMENT;
GUIDELINES AS TOPIC;
HUMANS;
MESENCHYMAL STROMAL CELLS;
SAFETY;
STEM CELL TRANSPLANTATION;
STEM CELLS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 84870700980
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.1229918 Document Type: Short Survey |
Times cited : (48)
|
References (22)
|